CLAIMS

1. Use of a peptide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a bacterial infection in a subject, wherein the peptide consists of between 10 to 50 arginine amino acid residues.

2. The use of claim 1, wherein one arginine amino acid residue of the peptide or the pharmaceutically acceptable salt thereof is substituted for another amino acid residue.

3. The use of claim 1 or 2, wherein the bacterial infection is caused by a pathogen selected from the group consisting of *Staphylococcus spp.*, e.g. *Staphylococcus aureus, Staphylococcus epidermidis*; *Enterococcus* spp., e.g. *Enterococcus faecalis*; *Streptococcus pyogenes*; *Listeria* spp.; *Pseudomonas spp.*; *Mycobacterium* spp., e.g. *Mycobacterium tuberculosis*; *Enterobacter* spp.; *Campylobacter* spp.; *Salmonella* spp.; *Streptococcus* spp., e.g. *Streptococcus* Group A or B, *Streptococcus pneumoniae*; *Helicobacter* spp., e.g. *Helicobacter pylori*; *Neisseria* spp., e.g. *Neisseria gonorrhea, Neisseria meningitidis*; *Borrelia burgdorferi; Shigella* spp., e.g. *Shigella flexneri; Escherichia coli*; *Haemophilus* spp., e.g. *Haemophilus influenzae; Chlamydia* spp., e.g. *Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci; Francisella tularensis; Bacillus* spp., e.g. *Bacillus anthracis*; *Clostridia* spp., e.g. *Clostridium botulinum*; *Yersinia* spp., e.g. *Yersinia pestis*; *Treponema* spp.; *Burkholderia* spp., e.g. *Burkholderia mallei, B pseudomallei* and *Propionibacterium spp.*.

4. The use of any one of the preceding claims, wherein the subject is a mammal.

5. The use of claim 4, wherein the mammal is a human.

6. The use of claim 1 or 2, wherein the bacterial infection is a dermal infection.

7. The use of claim 3, wherein the pathogen is selected from the group consisting of: *Staphylococcus aureus*; and *Staphylococcus epidermidis*.

8. The use of any one of the preceding claims, wherein the medicament is to be administered to the subject by a route selected from the group consisting of: oral, parenteral, rectal, dermal, transdermal, intrathoracic, intrapulmonary, and intranasal routes.

9. The use of claim 8, wherein the medicament is formulated for topical administration.